Trior develops a proprietary platform for antibody-drug conjugates aimed at improving the therapeutic index of ADC therapies. The company positions its technology as a next-generation approach to address limitations of existing ADCs. Trior is led by CEO Sungho Woo and has been active in investor outreach through incubator programs. It recently secured new capital as part of an ongoing Series B financing and has a cumulative Series B total of ₩25 billion. The company says it will use proceeds to continue development of its platform and to consolidate foundations for global commercialization. CKD Venture Investment’s participation was facilitated via Seoul Biohub programming and investor matchmaking.

Total raised

$2M

Funding rounds

1

Latest round

Series B

Latest activity

Aug 2025